Andrew H.

Andrew H. is a seasoned professional with extensive experience in the life sciences industry, currently serving as Chief Scientific Officer (CSO) at Cure JM Foundation since September 2018. Previously, Andrew held the role of CEO and President at Heaton-Brown Life Sciences from March 2017 to July 2019 and at Novogen North America from December 2012 to March 2017, where responsibilities included overseeing drug discovery and development programs. Prior to that, Andrew served as CEO at Triaxial Pharmaceuticals for a brief period in 2012, focusing on addressing shortcomings in the Novogen discovery platform. Andrew holds an Executive MBA from Melbourne Business School and advanced degrees in Organic Chemistry, including a Ph.D. from James Cook University and a B.Sc (Hons) from the University of Tasmania.